Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction A substudy of the Heart Outcomes Prevention Evaluation (HOPE) trial by Lonn, Eva et al.
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ffects of Ramipril on Left Ventricular
ass and Function in Cardiovascular
atients With Controlled Blood Pressure and
ith Preserved Left Ventricular Ejection Fraction
Substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial
va Lonn, MD, MSC, FACC, FRCPC,*† Roya Shaikholeslami, MD,*† Qilong Yi, PHD,†‡
ackie Bosch, MSC,† Brian Sullivan, MD, FRCPC,* Paul Tanser, MD, FACC, FRCPC,*
lison Magi, RN,† Salim Yusuf, MBBS, DPHIL, FACC, FRCPC*†
amilton and Toronto, Ontario, Canada
OBJECTIVES The purpose of this study was to assess the effects of ramipril on left ventricular mass (LVM)
and function in vascular disease patients with controlled blood pressure (BP) and with
preserved left ventricular ejection fraction (LVEF).
BACKGROUND Increased LVM and left ventricular (LV) volume and decreased LVEF predict clinical events.
Angiotensin-converting enzyme inhibitors reduce LVM and LV volume and preserve LVEF
in patients with hypertension and/or LV dysfunction, but have not been studied in patients
with controlled BP and preserved LVEF.
METHODS We compared the effects of two doses of ramipril (10 mg/day and 2.5 mg/day) versus placebo
in 506 patients with vascular disease on echocardiographic measures of LVM and LV
function.
RESULTS Baseline BP and LVEF were similar, 131/76 mm Hg and 58%, in all treatment groups. After
four years, LVM index increased by 3.98 2.08 g/m2 in the placebo and by 4.16 1.86 g/m2
in the ramipril 2.5 mg/day groups and decreased by 2.02  2.25 g/m2 in the ramipril 10
mg/day group (p  0.02). The changes in LV end-diastolic and end-systolic volumes were
4.16  2.55 ml and 5.31  1.67 ml in the placebo, 0.43  2.75 ml and 2.90  1.45 ml
in the ramipril 2.5 mg/day, and 5.90  2.93 ml and 1.90  1.55 ml in the ramipril 10
mg/day groups (p  0.02 and p  0.001). The changes in LVEF were 2.02  0.72%,
1.54  0.74%, and 0.17  0.72%, respectively (p  0.01).
CONCLUSIONS Ramipril has beneficial effects on LV structure and function in vascular patients with
controlled BP and with preserved LVEF. (J Am Coll Cardiol 2004;43:2200–6) © 2004 by
the American College of Cardiology Foundationp
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meft ventricular (LV) hypertrophy on electrocardiography or
ncreased left ventricular mass (LVM) on echocardiography
re strong predictors of death and nonfatal cardiovascular
vents in patients with hypertension, coronary heart disease,
ther cardiovascular diseases, and in the general population
1–5). Moreover, similar to other cardiovascular risk factors,
See page 2216
uch as cholesterol and blood pressure (BP), the relationship
etween LVM and cardiovascular risk may extend to in-
reases in LVM within the “normal” (average) range (5).
his may be particularly important in patients with other
arkers of increased cardiovascular risk, such as those with
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amilton, Ontario, Canada; †Population Health Research Institute, McMaster
niversity, Hamilton, Ontario, Canada; and the ‡Princess Margaret Hospital,
oronto, Ontario, Canada. The study was partially funded by the Medical Research
ouncil of Canada, grants UI-12362 and UI 12363.
Manuscript received July 14, 2003; revised manuscript received October 22, 2003,ccepted October 27, 2003.reexisting cardiovascular disease or those with multiple risk
actors. Similarly, increased LV volume and abnormal LV
ystolic function are potent predictors of events in patients
ith coronary heart disease (6–8).
Angiotensin-converting enzyme (ACE) inhibitors reduce
VM and regress LV hypertrophy in animal models and in
ypertensive human subjects (9–11). Similarly, ACE inhib-
tors have been shown to reduce LV volumes and to improve
V systolic function in patients with coronary heart disease
hen administered early after myocardial infarction or in
hose with low left ventricular ejection fraction (LVEF)
8,12). These beneficial effects of ACE inhibitor therapy on
VM and LV remodeling may be mediated through the
emodynamic, BP and afterload-reducing actions of these
gents, but also through load-independent mechanisms
elated to blockade of angiotensin II-mediated myocyte
ypertrophy, reduction in cardiac extracellular collagen ma-
rix formation attained by blocking angiotensin II, and by
ecrease in aldosterone release and through bradykinin-
ediated actions (13–15).
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June 16, 2004:2200–6 Ramipril Improves LV Structure and FunctionPatients with atherosclerotic vascular disease have in-
reased expression of tissue renin-angiotensin systems in the
asculature and in the heart (14,15), which could contribute
o an increase in LVM and to LV dilation. We postulated
hat chronic ACE inhibitor therapy would prevent an
ncrease in LVM and volumes and a decline in LV systolic
unction in patients with atherosclerotic vascular disease
ith average (“normal”) BP and LVM and with preserved
V systolic function. We further postulated that this effect
ould be largely independent of BP-lowering. We also
ought to evaluate the relationship between ramipril dose
nd its effects on LVM, volume, and function.
Therefore, we evaluated the effects of ramipril on LV
tructure and function in an echocardiographic substudy of
he Heart Outcomes Prevention Evaluation (HOPE) trial
16,17).
ETHODS
atients. Patients were recruited between December 1993
nd August 1995 from three Canadian HOPE study cen-
ers, selected based on expertise and interest in the study.
he study protocol was approved by the ethics board of each
articipating institution, and all patients provided informed
onsent. All of the HOPE study participants from these
enters who had technically adequate baseline echocardio-
rams were enrolled in the echocardiographic substudy.
ver 85% of patients were recruited at McMaster Univer-
ity, which also served as the core echocardiography labo-
atory. Detailed patient eligibility criteria for the HOPE
rial have been published (16,17). In summary, patients
ere eligible if they were55 years old, had vascular disease
r diabetes and at least one additional cardiovascular risk
actor and did not have heart failure symptoms, known low
VEF (40%), uncontrolled hypertension, renal disease
serum creatinine 200 mol/l or proteinuria), or other
ajor cardiac or noncardiac illness. To be eligible for the
chocardiographic substudy, patients had to have also an
dequate baseline echocardiographic examination, defined
s availability of recordings of good or fair quality for
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ASE  American Society of Echocardiography
BP  blood pressure
HOPE  Heart Outcomes Prevention Evaluation trial
LV  left ventricle/ventricular
LVEDV  left ventricular end-diastolic volume
LVEF  left ventricular ejection fraction
LVESV  left ventricular end-systolic volume
LVM  left ventricular mass
LVMI  left ventricular mass index
NWMAB  new wall motion abnormalities
WMS  wall motion score-mode and two-dimensional echocardiography, allowing teasurements of at least two of the echocardiographic
utcome measurements of LVM, LV volumes, and LVEF.
tudy design, randomization, interventions, and follow-
p. The echocardiographic substudy of the HOPE trial
as a randomized, double-blind, placebo-controlled trial
hat evaluated two doses of ramipril (2.5 mg/day and 10
g/day). Patients were also randomized to 400 IU/day of
itamin E or placebo, as part of the parent HOPE trial. The
tudy was designed to have 80% power to detect a change
f 10 g/m2 in left ventricular mass index (LVMI) assuming
standard deviation of 25 g/m2. Baseline echocardiograms
ere performed at the randomization visit. Follow-up visits
ccurred one month after randomization and every six
onths thereafter. Study-end echocardiograms were per-
ormed at the four-year visit. Blood pressure was measured
y experienced study nurses at randomization, one month,
wo years, and study end using standard sphygmomanom-
ters and a standardized protocol (study visits generally
ccurred during morning hours, use of appropriate cuff size
as ensured, patients were left alone supine for 5 min,
hereafter two exact readings avoiding rounding were ob-
ained from each arm, and the lowest readings from the left
nd right arms were averaged). The study protocol did not
nclude algorithms for the management of cardiovascular
isk factors, and the study drug dose was not titrated to
ttain predefined BP goals. The patients’ usual (clinical)
hysician(s) managed all cardiovascular risk factors, includ-
ng BP. The study protocol and the study personnel strongly
ecommended adherence to contemporary guidelines for the
anagement of cardiovascular risk factors. The open-label
se of ACE inhibitors for BP management alone was not
llowed. These agents could be used only when clear new
hanges in the patients’ clinical status occurred, for which
CE inhibitor therapy is generally strongly recommended.
f such clinical changes were transient, every effort was made
o discontinue treatment with open-label ACE inhibitors.
chocardiographic methods. Echocardiograms were ac-
uired by trained study sonographers following a standard-
zed protocol and using high-quality commercially available
chocardiographs equipped with 3.0- to 3.5-MHz and 2.0-
o 2.5-MHz probes. Standardized examinations included
wo-dimensional-guided M-mode recordings obtained in
he parasternal long- and short-axis views below the mitral
eaflet tips to the nearest millimeter and two-dimensional
arasternal long- and short-axis (at the mitral leaflets,
idpapillary, and apical levels) and apical (four-chamber,
wo-chamber, and long-axis) views. All measurements were
erformed off-line by one reader (R.S.) blinded to subjects’
andomization status and clinical data and using a comput-
rized review station (Freeland Systems, Cine View, Indi-
napolis, Indiana). A minimum of three cardiac cycles for
atients in sinus rhythm and five cardiac cycles for patients
n atrial fibrillation were captured and measured. The
-mode measurements included end-diastolic LV internal
iameter, interventricular septal thickness and posterior wall
hickness, and end-systolic and LV internal diameter. Cases
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Ramipril Improves LV Structure and Function June 16, 2004:2200–6here accurate M-mode measurements could not be ob-
ained in the parasternal short axis were substituted by
arasternal long-axis measurements. All M-mode measure-
ents were performed using the American Society of
chocardiography (ASE) leading-edge convention (18).
hen optimal orientation of the LV imaging views could
ot be obtained, correctly oriented two-dimensional linear
easurements were obtained using the ASE leading-edge
onvention. The LVM was calculated using the corrected
SE method (19), and LVMI was obtained by indexing for
ody surface area. Between-sonographer (on 83 duplicate
xaminations) and within-reader (on 80 duplicate readings)
ntraclass correlation coefficients for LVM were 0.84 and
.85, respectively. Two-dimensional LVM, left ventricular
nd-diastolic volume (LVEDV) and left ventricular end-
ystolic volume (LVESV), and LVEF were calculated from
wo-dimensional recordings using the modified biplane
impson’s method (20). Wall motion score (WMS) and
ew wall motion abnormalities (NWMAB) were evaluated
n two-dimensional echocardiograms using the 16-segment
odel (21). Between-sonographer and within-reader (on 20
uplicate readings) intraclass correlation coefficients for
VEF measurements were 0.70 and 0.75, respectively.
eproducibility of two-dimensional LVM measurements
as lower than that of M-mode measurements and, there-
ore, the latter were used for the primary analysis of
reatment effects on LVM and LVMI. An attempt was
ade to obtain all measurements from all echocardiograms
f all 446 patients included in the final analysis. However, at
imes the image quality was suboptimal. Consequently, not
ll measurements were obtained in every patient. M-mode
VM calculations were possible in 99% of the patients;
wo-dimensional measurements of LVEDV, LVESV,
VEF, LVM, and WMS were obtained in 98%, 98%, 98%,
6%, and 98% of patients, respectively.
Predefined echocardiographic outcome measurements
ere the changes between study end and baseline in LVM,
VMI, LVEDV, LVESV, LVEF, and WMS. In addition,
he effect of the study intervention on NWMAB was
valuated.
tatistical analysis. All analyses were by intention-to-treat
nd were done in SAS 8.0 (SAS Institute, Cary, North
arolina). Baseline characteristics were compared by one-
ay analysis of variance and chi-square tests as appropriate.
here was no significant interaction between ramipril and
itamin E for any of the echocardiographic measurements.
herefore, analyses were done to evaluate the overall impact
f ramipril on each predefined echocardiographic outcome
nd to compare differences between each of the two doses of
amipril versus placebo. The predefined primary analysis
as by analysis of variance, with changes in LVM, LVMI,
VEDV, LVESV, WMS, and NWMAB, respectively, as
he dependent variables and treatment assignment and
aseline measurements of the echocardiographic parameter
nalyzed as the independent variables. In addition, analyses
ontrolling for age, gender, and baseline echocardiographic ieasurements, for changes in systolic and in diastolic BP
nd with multivariate adjustment for baseline imbalances,
nd for other variables that may influence LVM and
unction (age, gender, body mass index, history of hyper-
ension, and history of coronary heart disease) were per-
ormed by analysis of covariance. The analysis evaluating the
verall ramipril effect used ramipril as a continuous variable
ith values of 0, 2.5 mg, and 10 mg in the model to test the
inear impact of ramipril on LVM and function. Dunnett’s
est for comparison of multiple treatments against one
ontrol was applied in the analyses comparing each dose of
amipril versus placebo. For all analyses, the level of statis-
ical significance was set at p  0.05.
ESULTS
aseline characteristics, follow-up, and compliance. A
otal of 506 patients were enrolled in the study. The baseline
haracteristics were well-balanced with the exception of
mall differences in body mass index and in history of
oronary heart disease (Table 1). A total of 446 patients
ompleted the study, 151 in the placebo, 149 in the ramipril
.5 mg/day, and 146 in the ramipril 10 mg/day groups.
heir baseline characteristics were similar to those of the
06 patients randomized and were also well-balanced.
Clinical follow-up was complete in all study patients. Of
he initial 506 study patients, 44 (9%) died, and 16 (3%)
issed the study-end echocardiogram due to illness or
hange in residence or had inadequate study-end echocar-
iograms. Thus, study-end echocardiograms were obtained
n 446 study participants (88% of all randomized patients
nd 97% of those alive at study end). Adherence and use of
on-study ACE inhibitors are shown in Table 2.
P changes. Both systolic and diastolic BP was well-
ontrolled at baseline, 131/76 mm Hg, and similar in the
hree treatment arms. Mean baseline, one month, two years,
nd study-end BP measurements are shown in Table 3.
ffects of ramipril on LVM and function. Ramipril
ignificantly reduced the change in LVM (p  0.03 for the
verall dose-dependent effect of ramipril in the analysis of
ariance analysis) and LVMI (p  0.02 for the overall effect
f ramipril). The benefit of ramipril therapy on LVM and
VMI remained statistically significant after adjustment for
ge, gender, and baseline LVM and LVMI, respectively,
nd after adjustment for changes in systolic and in diastolic
P (p  0.05). In the multivariate model adjusting for
aseline imbalances and predictors of LVM and function,
imilar trends were observed (p  0.08 for the change in
VM and in LVMI). The treatment benefit was derived
ntirely from the ramipril 10 mg/day group with no signif-
cant changes for the comparison between the ramipril 2.5
g/day versus placebo groups (Table 4). The mean differ-
nces in the changes in LVM and in LVMI between the
amipril 10 mg/day and placebo groups were 11.74 g and
.0 g/m2, respectively. The change in the sum of the
nterventricular septal thickness and posterior wall thick-
n
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June 16, 2004:2200–6 Ramipril Improves LV Structure and Functioness, which reflects the thickness of the myocardium and is
argely load-independent, was reduced by treatment with
amipril 10 mg/day (mean difference, 0.57 mm; p  0.05).
he main analyses of the treatment effect on changes in
able 1. Baseline Clinical and Echocardiographic Characteristics
Placebo
n  168
ge 65.5  6.8
Female 19.6
istory of (%)
Coronary heart disease* 85.7
Prior MI 59.5
Prior CABG 32.7
Hypertension 31.6
Diabetes 36.3
Dyslipidemia (high total cholesterol or
low HDL cholesterol)
54.2
Current smoking 9.6
Stroke 6.0
ystolic BP (mm Hg) 131.0  17.9
iastolic BP (mm Hg) 75.3  8.3
esting HR (beats/min) 66.2  10.8
MI (kg/m2)* 28.5  4.8
rug use (%)
Aspirin 85.1
Beta-blocker 44.1
Diuretics 9.5
Calcium channel blocker 19.1
Lipid lowering 35.7
aseline echocardiographic measurements
M-mode
IVST (mm) 9.93  2.01
PWT (mm) 9.30  1.63
LVIDd (mm) 53.86  6.33
LVM (g) 198.45  54.23
LVMI (g/m2) 101.89  24.43
LA (mm) 40.41  5.61
Two-dimensional
LVM (g) 174.09  48.97
LVMI (g/m2) 89.27  21.58
LVEDV (ml) 109.78  31.01
LVESV (ml) 47.10  18.80
LVEF (%) 57.86  9.44
WMS 1.20  0.26
p  0.05; †Only 14 patients (2.8%) had left ventricular ejection fraction (LVEF) 
BMI  body mass index; BP  blood pressure; CABG  coronary artery bypass
eptal thickness in end-diastole; LA  left atrial side; LVEDV  left ventricular end-
nternal diameter in end-diastole; LVM  left ventricular mass; LVMI  left ve
nd-diastole; WMS  left ventricular wall motion score.
able 2. Compliance (%)
Year Placebo Ramipril 2.5 mg/day Ramipril 10 mg/day
1 94.0 88.6 84.2
2 89.0 83.0 81.6
3 89.5 81.5 82.1
Study end 87.5 83.1 79.2
alues are percentages of patients taking 75% of study medications. Clinical
rogression of disease may have resulted in the need for open-label angiotensin-
onverting enzyme (ACE) inhibitors. Open-label ACE inhibitor use at any time
uring the study (including transient use) was 19.97% in the placebo, 14.8% in the
amipril 2.5 mg/day, and 13.0% in the ramipril 10 mg/day groups. The most common
auses for open-label ACE inhibitor use were the development of heart failure (25.0%
f all open-label ACE inhibitor use), new left ventricular dysfunction (19.1%), new or
orsening proteinuria (17.6%), and suboptimal blood pressure control after attemptsso control blood pressure without the use of ACE inhibitors (22.0%).VM and LVMI were derived from M-mode echocardi-
graphy. Data obtained from two-dimensional echocardi-
graphy also showed similar significant treatment benefits
or ramipril. The mean differences in two-dimensional
chocardiographic measurements of changes in LVM and in
VMI between the ramipril 10 mg/day and placebo groups
ere 14.06 g (p  0.03) and 7.21 g/m2 (p  0.03),
espectively.
The LVEDV and LVESV increased over time in the
lacebo arm of the trial, but decreased in the ramipril 10
g/day group, with similar but statistically not significant
rends for the ramipril 2.5 mg/day group (Table 4). The
verall treatment effect of ramipril and the effect of ramipril
0 mg/day on changes in LVEDV and in LVESV remained
tatistically significant after adjusting for age, gender, and
aseline LVEDV and LVESV, respectively, for changes in
Ramipril 2.5 mg/day
n  171
Ramipril 10 mg/day
n  167
65.3  6.6 65.3  6.3
24.6 25.8
88.3 78.4
61.4 56.3
33.9 26.4
31.6 40.7
31.0 37.1
51.5 52.1
9.9 10.8
5.3 5.4
130.2  17.2 131.4  15.2
76.5  9.9 75.9  9.6
66.5  10.9 66.6  10.9
27.1  3.6 28.1  4.5
84.8 77.8
41.5 43.7
11.7 12.0
11.1 16.8
38.6 27.0
9.89  1.85 10.15  2.01
9.03  1.50 9.23  1.49
53.40  6.31 53.73  6.84
190.30  51.07 199.48  59.13
101.02  24.15 103.42  27.57
39.47  4.92 40.20  5.20
172.54  50.07 179.31  56.84
91.81  24.56 93.73  24.82
108.38  36.66 110.04  44.66
46.59  22.81 49.77  26.07
58.38  8.83 58.21  9.58
1.23  0.30 1.17  0.24
at baseline.
rgery; HDL  high-density lipoprotein; HR  heart rate; IVST  interventricular
lic volume; LVESV  left ventricular end-systolic volume; LVIDd  left ventricular
lar mass index; MI  myocardial infarction; PWT  posterior wall thickness in40%
graft su
diasto
ntricuystolic and in diastolic BP and in the multivariate model.
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Ramipril Improves LV Structure and Function June 16, 2004:2200–6he differences in LVEDV and LVESV between the
amipril 10 mg/day and the placebo groups were 10.06 ml
p  0.019) and 7.21 ml (p  0.002), respectively.
Baseline LVEF was well-preserved and similar, 58%, in
ll three study groups. In patients assigned to the placebo
rm of the trial, there was a 2% loss in LVEF over time,
ith only minimal 0.17% loss in LVEF in the ramipril 10
g/day group and an intermediate 1.5% loss in LVEF in
he ramipril 2.5 mg/day group (Table 3). The effect of
amipril was statistically significant (p  0.009 for the
verall dose-dependent ramipril effect adjusted for baseline
VEF, p  0.011 in the model adjusted for age, gender,
nd baseline LVEF, p  0.025 in the multivariate model,
nd p  0.062 in the model adjusted for time-dependent
hanges in systolic and in diastolic BP). The mean differ-
nce between changes in LVEF in the ramipril 10 mg/day
nd placebo groups was 1.85% (p  0.018). There were
imilar trends towards better WMS and fewer NWMAB in
he ramipril 10 mg/day group, although these did not reach
tatistical significance (Table 4).
In order to better understand the observed treatment
enefit on LVEF, we evaluated the effects of ramipril in
atients who did and those who did not sustain a myocardial
nfarction during the study. Of the 446 patients who
ompleted both echocardiographic examinations, 39 sus-
ained a myocardial infarction (16 in the placebo, 12 in the
amipril 2.5 mg/day, and 11 in the ramipril 10 mg/day
Table 3. Systolic and Diastolic Blood Pressure
Baseline
Systolic BP, mm Hg
Placebo 131.0  17.9 1
Ramipril 2.5 mg/day 130.3  16.7 1
Ramipril 10 mg/day 131.3  15.1 1
Diastolic BP, mm Hg
Placebo 75.3  8.3
Ramipril 2.5 mg/day 76.5  9.9
Ramipril 10 mg/day 75.9  9.6
Values are mean  SD. *p  0.05, †p  0.01, ‡p  0.001,
(BP). Compared with the placebo group, the systolic and di
month and two years but not at study end in the ramipril 2.
not differ significantly between the ramipril 2.5 mg/day and
Table 4. Effects of Ramipril on Left Ventricul
Placebo
n  151
Ramipril 2.
n  1
LVM (g) 8.21  4.01 7.86 
LVMI (g/m2) 3.98  2.08 4.16 
LVEDV (ml) 4.16  2.55 0.43 
LVESV (ml) 5.31  1.67 2.90 
LVEF (%) 2.02  0.72 1.54 
WMS 0.05  0.01 0.029 
NWMAB 31 (20.8%) 30 (20
Values are means  SEM; all changes () in echocardiograph
*Corrected for baseline value; †p  0.05 for the comparison o
of ramipril 10 mg/day versus placebo; §p  0.06 for the com
LVEDV  change in left ventricular end-diastolic vol
change in left ventricular ejection fraction measured by t
ventricular end-systolic volume measured by two-dimension
measured by M-mode echocardiography; LVMI  change
raphy; WMS  change in wall motion score; NWMAB  newroups), and their LVEF changes did not differ signifi-
antly, probably due to the small number of observations
nd the limited power of this analysis. Among the 407
atients who did not sustain a myocardial infarction during
he study, there was a significant treatment effect (p 0.028
or the overall dose-dependent ramipril effect and p 0.019
or the comparison between the ramipril 10 mg/day and the
lacebo groups). These differences remained statistically
ignificant in the model adjusted for age, gender, and
aseline LVEF and in the multivariate model, with a strong
rend (p 0.06) in the analysis corrected for systolic and for
iastolic BP changes.
linical outcomes. As expected in this relatively small
ubstudy, there were no statistically significant differences in
he primary clinical outcome (the composite of cardiovas-
ular death, myocardial infarction, and stroke) that occurred
n 32 patients (19.1%) in the placebo, 24 (14%) in the
amipril 2.5 mg/day, and 25 (15%) in the ramipril 10
g/day groups. Reliable data on clinical outcomes are
rovided by the adequately powered parent HOPE trial
17).
ISCUSSION
e demonstrated that long-term therapy with the ACE
nhibitor ramipril has favorable effects on LV structure and
unction, by reducing LVM, LV volumes, and the loss in
aseline and in Follow-Up
onth 2 Years Study End
 17.9† 129.8  16.1 134.2  18.3†
 16.7§ 123.6  15.5§ 130.6  16.6
 15.4§ 125.9  17.3‡ 132.5  17.3
 9.5 74.0  9.9 72.5  8.9†
 9.7‡ 71.5  9.1§ 72.0  8.5§
 8.9* 71.7  8.9§ 72.6  9.4‡
p  0.0001 for comparisons versus baseline blood pressure
BP changes versus baseline were significantly higher at one
ay and 10 mg/day groups. The blood pressure changes did
/day groups.
ass and Function
/day Ramipril 10 mg/day
n  146 p for Trend*
3.53  4.40† 0.03
2.02  2.25† 0.02
5.90  2.93† 0.02
1.90  1.55‡ 0.001
0.17  0.72† 0.01
0.018  0.01§ 0.06
23 (15.8%) 0.24
asurements are calculated as study end minus baseline values.
pril 10 gm/day versus placebo; ‡p  0.01 for the comparison
on of ramipril 10 mg/day versus placebo.
easured by two-dimensional echocardiography; LVEF 
mensional echocardiography; LVESV  change in left
ocardiography; LVM  change in left ventricular mass
ventricular mass index measured by M-mode echocardiog-at B
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ell-controlled BP, and with average (“normal”) baseline
VM, LV volume, and LVEF. These are novel observa-
ions, as previous clinical ACE inhibitor studies have
elected patients based on elevated BP and/or increased
VM or depressed LV systolic function. Furthermore, in
uch previous trials, ACE inhibitor dose was generally
itrated based on BP response.
Both ramipril 10 mg/day and 2.5 mg/day had significant,
ut modest, BP-lowering effects at one month and at two
ears after randomization although, by study end, systolic
P returned to baseline levels in the active treatment groups
nd increased in the placebo group. The magnitude of
P-lowering was similar for the two ramipril doses, which
ay be related to the fact that most study patients were
aking various other anti-ischemic drugs at different doses,
ot controlled by the study protocol. By contrast, the
enefits of ramipril on LVM, LV volumes, and LV function
ere observed with the higher dose of 10 mg/day, while the
ower dose of 2.5 mg/day did not have a significant impact.
hese observations suggest that the benefits of ACE inhib-
tor therapy on LVM and function are, at least in part,
ndependent of BP-lowering. Furthermore, statistical anal-
ses adjusting for BP changes did not significantly alter the
tudy results for the analyses of treatment effects on LVM
nd LV volumes, while for LVEF a strong trend towards
reatment benefit remained after correcting for changes in
P (p  0.06), and the multivariate model, which included
istory of hypertension, remained statistically significant. In
he multivariate model, which adjusted for baseline LVM,
ge, gender, and for baseline imbalances and other predic-
ors of LVM, there was a strong trend for an overall ramipril
ffect on LVM and LVMI (p  0.08). While this analysis
id not reach traditional levels of statistical significance, a
trong trend was observed; this analysis is conservative and
ontrols not only for parameters that differed at baseline,
nd, furthermore, the comparison between the ramipril 10
g/day and the placebo groups was significant in the
ultivariate model.
The beneficial effect of ramipril on LVEF was not
estricted to patients who had an interim infarct during the
tudy. This analysis suggests that the impact of ramipril on
reservation of LV systolic function is likely multifactorial
nd cannot be explained by prevention of new infarcts or
eduction in BP alone.
Previous studies in hypertensive patients have reported
eak correlations between changes in LVM and drug-
nduced BP reductions, and it was suggested that LVM
hanges more closely relate to changes in 24-h than to
office” BP and that clinical trials may underestimate the
mpact of intrapatient variability in BP reduction on LVM
hanges (22,23). However, these studies have studied pa-
ients selected based on elevated baseline BP, while in our
rial a history of hypertension was present in only 33% of the
tudy participants, and BP was, on average, well-controlled,
31/76 mm Hg.The mean difference in change over four years in LVMI
etween the placebo and ramipril 10 mg/day groups was 6
/m2, which is less than observed in some BP-lowering
rials (22). However, such trials have selected patients who
ere hypertensive and had baseline LV hypertrophy, while,
n our study, patient selection was based on cardiovascular
isk alone, and most patients had average (“normal”) base-
ine BP and LVM.
Our findings are concordant with other analyses of the
OPE trial and with previous investigations. Thus, in the
OPE trial, ramipril caused prevention or regression of LV
ypertrophy defined on electrocardiography, an effect that
as largely independent of BP changes (24). Other clinical
rials have also shown regression of LV hypertrophy with
CE inhibitors in hypertensive populations and some
10,11,25), although not all such trials (22), suggest that, for
imilar degrees of BP-lowering, these agents may be more
ffective than other antihypertensive agents in reducing LV
ypertrophy.
The mechanism of reduction in LVM with ACE inhib-
tor therapy is likely multifactorial. Angiotensin II is a
otent vasoconstrictor, has positive inotropic actions on the
eart muscle, and can further affect cardiac hemodynamics
y potentiating the actions of the sympathetic nervous
ystem (13,14). In addition, both circulating and locally
roduced angiotensin II has a direct trophic effect on
yocardial smooth muscle cells and contributes to restruc-
uring and proliferation of the myocardial extracellular
ollagen matrix, thus promoting LV hypertrophy. The
CE inhibitors can prevent or regress LV hypertrophy
hrough hemodynamic afterload reducing actions, but also
hrough load-independent mechanisms, as shown in animal
odels (13,14,26,27).
The reduction in LV volume and the preservation of LV
ystolic function observed in our study are also consistent
ith the reduced rates of heart failure in the parent HOPE
rial (28) and with previous studies (8,12) and is related to
he hemodynamic afterload-reducing effect of ramipril, but
lso to the prevention of new infarcts, to the benefit on
yocardial remodeling, and to the general stabilizing effect
f ACE inhibition on atherosclerosis (13,15). As shown in
xperimental studies, these effects are related to blockade of
ngiotensin II type 1 receptor-mediated actions, but also to
ncreased availability of bradykinin and possibly additional
CE inhibitor effects (13–15,29).
In summary, our study shows a significant dose-
ependent, but, at least in part, BP-independent beneficial
ffect of ACE inhibitor therapy on LV structure and
unction. These results parallel similar findings on the
revention of clinical events with ramipril observed in the
arent HOPE trial, which was only partly explained by BP
eduction. These data provide further evidence supporting
he use of long-term ACE inhibitor therapy in a wide range
f patients with cardiovascular disease.
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